Description: Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Home Page: www.clearmindmedicine.com
1220 West 6th Avenue
Vancouver,
BC
V6H 1A5
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Exec. Officer |
| Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA | CFO & Director |
| Mr. Gilad Babchuk | Head of Strategy & Communication |
| Prof. Mark Haden | VP of Bus. Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 39.0808 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |